| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2016: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
|
|---|
| Outline of Final Research Achievements |
The purpose of this work is to perform the reactant early evaluation in molecular target drugs, and an exploitation of a surgery support liver-function imaging using MRI. To evaluate and compare the usefulness of equivalent cross-relaxation rate (ECR) imaging (ECRI) in the early prediction of the response of molecular target drugs treatments of colorectal liver metastases. In the response assessment to chemotherapy, the pretreatment ECR values were significantly higher in the responders group than in the non-responders group, and the 2 weeks after the ECR values were significantly lower. To evaluate posthepatectomy liver failure using gadoxetic acid-enhanced MRI with a measure of relative liver enhancement image (RLEI) on hepatobiliary phase images, thereby facilitating safe liver resection. This MRI examination method also provides morphological and functional information that can be used to optimize the preoperative selection of patients who can safely undergo liver resection.
|
